Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis

por Lam, KH, van Oirschot, P, den Teuling, B, Hulst, HE, de Jong, BA, Uitdehaag, BMJ, de Groot, V, Killestein, J
Publicado 2021

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

por Killestein, J., Vennegoor, A., van Golde, A. E. L., Bourez, R. L. J. H., Wijlens, M. L. B., Wattjes, M. P.
Publicado 2014

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis

por Lam, KH, Meijer, KA, Loonstra, FC, Coerver, EME, Twose, J, Redeman, E, Moraal, B, Barkhof, F, de Groot, V, Uitdehaag, BMJ, Killestein, J
Publicado 2020

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

por van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE
Publicado 2021

Information processing speed in multiple sclerosis: Relevance of default mode network dynamics

por van Geest, Q., Douw, L., van 't Klooster, S., Leurs, C.E., Genova, H.M., Wylie, G.R., Steenwijk, M.D., Killestein, J., Geurts, J.J.G., Hulst, H.E.
Publicado 2018

Predicting clinical progression in multiple sclerosis after 6 and 12 years

por Dekker, I., Eijlers, A. J. C., Popescu, V., Balk, L. J., Vrenken, H., Wattjes, M. P., Uitdehaag, B. M. J., Killestein, J., Geurts, J. J. G., Barkhof, F., Schoonheim, M. M.
Publicado 2019

Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanne...

por Weeda, M.M., Middelkoop, S.M., Steenwijk, M.D., Daams, M., Amiri, H., Brouwer, I., Killestein, J., Uitdehaag, B.M.J., Dekker, I., Lukas, C., Bellenberg, B., Barkhof, F., Pouwels, P.J.W., Vrenken, H.
Publicado 2019

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis

por Hartung, H-P, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Ross, A Perrin, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q, Freedman, MS
Publicado 2020

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?

por van Kempen, Z.L.E., Wieske, L., Stalman, E.W., Kummer, L. Y. L, van Dam, P.J., Volkers, A.G., Boekel, L., Toorop, A.A., Strijbis, E.M.M., Tas, S.W., Wolbink, G.J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N.J.M., Steenhuis, M., Kuijpers, T.W., van Ham, S.M., Rispens, T., Eftimov, F., Killestein, J.
Publicado 2022

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study

por Leurs, CE, Twaalfhoven, HAM, Lissenberg-Witte, BI, van Pesch, V, Dujmovic, I, Drulovic, J, Castellazzi, M, Bellini, T, Pugliatti, M, Kuhle, J, Villar, LM, Alvarez-Cermeño, JC, Alvarez-Lafuente, R, Hegen, H, Deisenhammer, F, Walchhofer, LM, Thouvenot, E, Comabella, M, Montalban, X, Vécsei, L, Rajda, C, Galimberti, D, Scarpini, E, Altintas, A, Rejdak, K, Frederiksen, JL, Pihl-Jensen, G, Jensen, PEH, Khalil, M, Voortman, MM, Fazekas, F, Saiz, A, La Puma, D, Vercammen, M, Vanopdenbosch, L, Uitdehaag, BMJ, Killestein, J, Bridel, C, Teunissen, C
Publicado 2019